TY - JOUR
T1 - The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles
AU - Galli De Amorim, Maria
AU - Branco, Gabriela
AU - Valieris, Renan
AU - Tarcitano, Emilio
AU - Tojal Da Silva, Israel
AU - Ferreira De Araújo, Luiza
AU - Noronha Nunes, Diana
AU - Dias-Neto, Emmanuel
N1 - Publisher Copyright:
© 2019 Future Medicine Ltd.
PY - 2019/5/24
Y1 - 2019/5/24
N2 - HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.
AB - HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.
UR - http://www.scopus.com/inward/record.url?scp=85066117079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066117079&partnerID=8YFLogxK
U2 - 10.2217/pgs-2018-0182
DO - 10.2217/pgs-2018-0182
M3 - Article
C2 - 31124410
AN - SCOPUS:85066117079
SN - 1462-2416
VL - 20
SP - 493
EP - 502
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 7
ER -